Vyant Bio : Third Quarter 2022 Conference Call & Webcast

H U M A N - P O W E R E D D R U G D I S C O V E R Y

Nasdaq: VYNT

Q3 2022

S A F E H A R B O R

This presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements involve known and unknown risks and uncertainties that exist in our operations and business environment, which may be beyond our control, and which may cause actual results, performance or achievements to be materially different from future results, performance or achievements expressed or implied by such forward-looking statements. All statements other than statements of historical fact are statements that could be forward- looking statements. For example, forward-looking statements include, without limitation: statements pertaining to Vyant Bio, Inc.'s expectations regarding future financial and/or operating results, the efficacy of our drug screening and discovery process, potential for our services, future revenues or growth and plans, strategies and objectives of management for future operations or transactions. The risks and uncertainties referred to above include, but are not limited to, risks detailed from time to time in our filings with the Securities and Exchange Commission, including our Annual Report on Form 10-K for the year ended December 31, 2021 and any subsequent filings. These risks could cause actual results to differ materially from those expressed in any forward-looking statements made by, or on behalf of, Vyant Bio. Forward-looking statements represent the judgment of the Company's management regarding future events. Although the we believe that the expectations reflected in such forward- looking statements are reasonable at the time that they are made, we can give no assurance that such expectations will prove to be correct. Unless otherwise required by applicable law, the Company assumes no obligation to update any forward-looking statements, and expressly disclaims any obligation to do so, whether as a result of new information, future events or otherwise.

Nasdaq: VYNT	2

Human microOrgan™ Discovery Platform

Paradigm for high-throughputclinic-based screening

Drive Successful Clinical Outcomes Through Patient-Based Discovery

Discovery

Patient-derived iPSC Organoids

Establish translatable bio-markers to drive Discovery and de-risked clinical trials

Biomarker-based Screening

Identify, validate, and de-risk targets and hits across multiple biological endpoints

Targets & Hits

Novel & Repurposed

Value Creation

Rapidly discover and advance first and/or best in class targets and molecules

Utilize patient biology, high-throughput screening and data

science to drive de-risked target and hit discovery

Nasdaq: VYNT

3

THIRD QUARTER 2022 HIGHLIGHTS

2017

2019

Engaging with the International Rett Syndrome Foundation

• POC clinical trails

Sale completed of US vivoPharm business

Insightful data readouts on disease phenotype in Rett Syndrome and CDKL5

Presented:

Investor Conferences

Loulou Foundation

Neuroscience 2022

Nasdaq: VYNT

4

Therapeutic Pipeline

							IND
	Our Therapeutic Assets			P R E C L I N I C A L		C L I N I C A L
	PROGRAM	INDICATION	EARLY DISCOVERY	TARGET ID & VALIDATION	LEAD ID	LEAD OPTIMIZATION	PHASES 1, 2, 3
	VYNT-0126	Rett Syndrome
	ORAI-xxxx *	Rett Syndrome
	VYNT-xxxx *	CDKL5
	VYNT-xxxx	Parkinson's Disease

• We are in partnerships for the use of artificial intelligence systems with Atomwise for the discovery of a novel Rett Syndrome compound and Cyclica for the discovery of a novel CDKL5 compound

Nasdaq: VYNT

5